Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Berenjeno, Inma M ^a   Piñeiro, Roberto ^a,b   Castillo, Sandra D ^a   Pearce, Wayne ^a   McGranahan, Nicholas ^c   Dewhurst, Sally M ^c   Meniel, Valerie ^d   Birkbak, Nicolai J ^c   Lau, Evelyn ^a   Sansregret, Laurent ^a,c   Morelli, Daniele ^a   Kanu, Nnennaya ^c   Srinivas, Shankar ^e   Graupera, Mariona ^f   Parker, Victoria E R ^g   Montgomery, Karen G ^h   Moniz, Larissa S ^a   Scudamore, Cheryl L ⁱ   Phillips, Wayne A ^h   Semple, Robert K ^g   Clarke, Alan ^d   Swanton, Charles ^a,c   Vanhaesebroeck, Bart ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ Medical Research Council Harwell Institute   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; DIHYDROCYTOCHALASIN B; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RECOMBINASE; TAMOXIFEN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PIK3CA PROTEIN, MOUSE;

CANCER; GENE EXPRESSION; GENOME; HETEROGENEITY; MUTATION; PROTEIN; TUMOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL DIVISION; CENTROSOME; CHROMOSOME SEGREGATION; CONTROLLED STUDY; DNA REPLICATION; EMBRYO; ENZYME ACTIVATION; GENE AMPLIFICATION; GENE TARGETING; HUMAN; IN VITRO STUDY; KINETOCHORE MICROTUBULE; LETHALITY; METAPHASE CHROMOSOME; MOUSE; NONHUMAN; PI3K/AKT SIGNALING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME; UPREGULATION; ANIMAL; BREAST TUMOR; C57BL MOUSE; COHORT ANALYSIS; ENZYMOLOGY; FEMALE; GENETICS; GENOME; MALE; METABOLISM; MUTATION; ONCOGENE;

ANIMALS; BREAST NEOPLASMS; CENTROSOME; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COHORT STUDIES; FEMALE; GENE AMPLIFICATION; GENOME; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUTATION; ONCOGENES; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 85035076589     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-02002-4     Document Type: Article

References (57)

1. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
2. Burke, J. E., Perisic, O., Masson, G. R., Vadas, O. & Williams, R. L. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc. Natl Acad. Sci. USA 109, 15259-15264 (2012).
3. Kang, S., Bader, A. G., Zhao, L. & Vogt, P. K. Mutated PI 3-kinases: cancer targets on a silver platter. Cell Cycle 4, 578-581 (2005).
4. Vanhaesebroeck, B., Whitehead, M. A. & Pineiro, R. Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J. Mol. Med. 94, 5-11 (2016).
5. Okkenhaug, K., Graupera, M. & Vanhaesebroeck, B. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discov. 6, 1090-1105 (2016).
6. Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7-24 (2015).
7. Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140-156 (2014).
8. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
9. Kinross, K. M. et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Invest. 122, 553-557 (2012).
10. Koren, S. & Bentires-Alj, M. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors. FEBS J. 280, 2758-2765 (2013).
11. Fukasawa, K. Oncogenes and tumour suppressors take on centrosomes. Nat. Rev. Cancer 7, 911-924 (2007).
12. Gonczy, P. Centrosomes and cancer: revisiting a long-standing relationship. Nat. Rev. Cancer 15, 639-652 (2015).
13. Fujiwara, T. et al. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437, 1043-1047 (2005).
14. Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4, 175-185 (2014).
15. Sercin, O. et al. Transient PLK4 overexpression accelerates tumorigenesis in p53-deficient epidermis. Nat. Cell Biol. 18, 100 (2016).
16. Coelho, P.A. et al. Over-expression of Plk4 induces centrosome amplification, loss of primary cilia and associated tissue hyperplasia in the mouse. Open Biol. 5, 150209 (2015).
17. Levine, M. S. et al. Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals. Dev. Cell 40, 313-322 (2017).
18. Moniz, L. S. et al. Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate. Sci. Rep. 7, 39985 (2017).
19. Dymecki, S. M. Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice. Proc. Natl Acad. Sci. USA 93, 6191-6196 (1996).
20. Hunter, N. L., Awatramani, R. B., Farley, F. W. & Dymecki, S. M. Ligand-activated Flpe for temporally regulated gene modifications. Genesis 41, 99-109 (2005).
21. Lindhurst, M. J. et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat. Genet. 44, 928-933 (2012).
22. Hare, L. M. et al. Heterozygous expression of the oncogenic Pik3ca(H1047R) mutation during murine development results in fatal embryonic and extraembryonic defects. Dev. Biol. 404, 14-26 (2015).
23. Yuan, W. et al. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32, 318-326 (2013).
24. Tikoo, A. et al. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERalpha-positive tumors. PLoS ONE 7, e36924 (2012).
25. Hare, L. M. et al. Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. Biochem. J. 458, 251-258 (2014).
26. Doxsey, S., Zimmerman, W. & Mikule, K. Centrosome control of the cell cycle. Trends Cell Biol. 15, 303-311 (2005).
27. Manning, J. A. & Kumar, S. A potential role for NEDD1 and the centrosome in senescence of mouse embryonic fibroblasts. Cell Death Dis. 1, e35 (2010).
28. Ma, Z. et al. Interaction between ROCK II and nucleophosmin/B23 in the regulation of centrosome duplication. Mol. Cell Biol. 26, 9016-9034 (2006).
29. Hanashiro, K., Brancaccio, M. & Fukasawa, K. Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification. Oncogene 30, 2188-2197 (2011).
30. Tokuyama, Y., Horn, H. F., Kawamura, K., Tarapore, P. & Fukasawa, K. Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J. Biol. Chem. 276, 21529-21537 (2001).
31. Brinkley, B. R. Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol. 11, 18-21 (2001).
32. Kwon, M. et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev. 22, 2189-2203 (2008).
33. Ganem, N. J., Godinho, S. A. & Pellman, D. A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278-282 (2009).
34. Ganem, N. J. et al. Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell 158, 833-848 (2014).
35. Aylon, Y. & Oren, M. p53: guardian of ploidy. Mol. Oncol. 5, 315-323 (2011).
36. Thompson, S. L. & Compton, D. A. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J. Cell Biol. 188, 369-381 (2010).
37. McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra254 (2015).
38. Morris, L. G. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051-10063 (2016).
39. Nam, H. J., Chae, S., Jang, S. H., Cho, H. & Lee, J. H. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis 31, 1531-1540 (2010).
40. Adams, J. R. et al. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res. 71, 2706-2717 (2011).
41. Van Keymeulen, A. et al. Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. Nature 525, 119-123 (2015).
42. Vitre, B. D. & Cleveland, D. W. Centrosomes, chromosome instability (CIN) and aneuploidy. Curr. Opin. Cell Biol. 24, 809-815 (2012).
43. Godinho, S.A. & Pellman, D. Causes and consequences of centrosome abnormalities in cancer. Philos. Trans. R Soc. Lond. B Biol. Sci. 369, 20130467 (2014).
44. Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561-573 (2005).
45. Liu, H., Radisky, D. C., Wang, F. & Bissell, M. J. Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J. Cell Biol. 164, 603-612 (2004).
46. Davoli, T. & de Lange, T. The causes and consequences of polyploidy in normal development and cancer. Annu. Rev. Cell Dev. Biol. 27, 585-610 (2011).
47. Ganem, N. J., Storchova, Z. & Pellman, D. Tetraploidy, aneuploidy and cancer. Curr. Opin. Genet. Dev. 17, 157-162 (2007).
48. Borel, F., Lohez, O. D., Lacroix, F. B. & Margolis, R. L. Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc. Natl Acad. Sci. USA 99, 9819-9824 (2002).
49. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
50. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134-1140 (2013).
51. Fritsch, C. et al. Characterization of the novel and specific PI3Kalpha inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13, 1117-1129 (2014).
52. Berenjeno, I. M. et al. Both p110alpha and p110beta isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem. J. 442, 151-159 (2012).
53. Lichti, U., Anders, J. & Yuspa, S. H. Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice. Nat. Protoc. 3, 799-810 (2008).
54. Shibata, H. et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278, 120-123 (1997).
55. el Marjou, F. et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 39, 186-193 (2004).
56. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289-1295 (2005).
57. Higginbotham, H., Bielas, S., Tanaka, T. & Gleeson, J. G. Transgenic mouse line with green-fluorescent protein-labeled Centrin 2 allows visualization of the centrosome in living cells. Transgenic Res. 13, 155-164 (2004).